NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MODD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise and manage capital to fund operations | A primary condition in Modular Medical Inc's published investment case. The stated target is Raise approximately $3.38 million in 2026-Q4 and maintain $0.35 million credit facility in 2026-Q1. | Intact | Fail to raise $3.38 million or lose $0.35 million credit facility by 2026-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business rather than a proven durable compounder. The long-term thesis is marked intact, but confidence is low and evidence of progress on losses remains limited.
The snapshot does not provide a valuation measure or specific market expectations, so whether MODD is cheap or expensive versus peers cannot be assessed. Its ongoing losses and financing needs are clear, but the market’s expectations for improvement are not specified.
Near term, repeated earnings misses and elevated miss risk make another weak report a concern. Operating losses and negative cash flow have persisted, while a recent equity offering shows continued need for capital; the evidence points to limited progress so far.
Over the next few quarters, the key company-level test is whether management can reduce operating losses and cash use while handling capital needs and leadership changes. The broader setup also depends on jobs data and Healthcare bellwethers: weakening employment or weaker results from ABT, MDT, and SYK could erode the sector tailwind, while continued strong results could support it.
For the next 1 to 3 years, MODD’s thesis rests on progress toward lower losses and less dependence on external capital, but current evidence is thin and near-term execution risk is high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stabilize executive leadership and governance |
| A supporting condition in Modular Medical Inc's published investment case. The stated target is No major leadership disruptions and stable governance in 2026. |
| Intact |
| Significant leadership turmoil or governance issues in 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses and negative cash flow | A primary condition in Modular Medical Inc's published investment case. The stated target is Operating income better than -$5.68 million and cash flow better than -$5.82 million by 2026-Q4. | Broken | Operating income or cash flow worse than targets in 2026-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.